NUC 1031

Drug Profile

NUC 1031

Alternative Names: Acelarin; CPF-31; Gemzar ProTide - NuCana; MTL-007; NUC-1031

Latest Information Update: 08 Aug 2016

Price : $50

At a glance

  • Originator Cardiff University
  • Developer Imperial College of Science, Technology and Medicine; NuCana
  • Class Antineoplastics
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Ovarian cancer
  • Phase I/II Solid tumours
  • Phase I Biliary cancer; Bladder cancer; Non-small cell lung cancer

Most Recent Events

  • 22 Jul 2016 Phase-I clinical trials in Ovarian cancer (Combination therapy) (IV) (NuCana pipeline, July 2016)
  • 22 Jul 2016 Phase-II clinical trials in Ovarian cancer (Monotherapy) (IV) (NuCana pipeline, July 2016)
  • 06 Jun 2016 Interim efficacy and adverse events data from the phase Ib ProGem2 trial in Ovarian cancer presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top